---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-046522"
form_type: "8-K"
ticker: null
cik: "0001845337"
company_name: "Day One Biopharmaceuticals, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:20:32.200396+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Day One Biopharmaceuticals amends bylaws for universal proxy rules and DGCL updates

## Summary
- Bylaws revised to comply with SEC universal proxy rules (Rule 14a-19) and recent Delaware law changes.
- Advance notice provisions updated: additional disclosures, nominee interview requirement, proxy card color rule.
- Stockholders using universal proxy must certify compliance and provide evidence 5 business days before meeting.
- Emergency bylaw provision added to allow Board quorum during crises.
- Changes effective Feb 17, 2023; no impact on financials or operations.

## SEC filing metadata
- accession: 0001193125-23-046522
- form_type: 8-K
- cik: 0001845337
- company_name: Day One Biopharmaceuticals, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/0001193125-23-046522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/d467705d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-046522
- JSON: https://secwatch.observer/filing/0001193125-23-046522.json
- Plain text: https://secwatch.observer/filing/0001193125-23-046522.txt

## Key facts
- Governance Changes
  Day One Biopharmaceuticals, Inc.: Amended and restated bylaws to align with universal proxy rules, DGCL amendments, and other changes (effective 2023-02-17).
  - Change: bylaw amendment
  - Effective: 2023-02-17
  source text: On February 17, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Day One Biopharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/0001193125-23-046522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.